Targeting Microtubule-associated Protein Tau (MAPT) Interactors for Novel Therapeutic Interventions for Rapidly Progressive Alzheimer’s Disease / (Record no. 607697)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02284nam a22001577a 4500 |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 610 |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Fatimah |
| 245 ## - TITLE STATEMENT | |
| Title | Targeting Microtubule-associated Protein Tau (MAPT) Interactors for Novel Therapeutic Interventions for Rapidly Progressive Alzheimer’s Disease / |
| Statement of responsibility, etc. | Fatimah |
| 264 ## - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Islamabad : |
| Name of producer, publisher, distributor, manufacturer | SMME- NUST; |
| Date of production, publication, distribution, manufacture, or copyright notice | 2022. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 74p. |
| Other physical details | Soft Copy |
| Dimensions | 30cm |
| 500 ## - GENERAL NOTE | |
| General note | Rapidly Progressive Alzheimer's disease (rpAD) is a disease characterized by rapid cognitive<br/>loss. It progresses quickly over the course of weeks to months and sometimes may take up to<br/>two to three years. It’s rare and difficult to diagnose although accurate diagnosis is extremely<br/>crucial for its treatment. Recent evidence suggests Tau as a promising therapeutic agent for the<br/>development of disease-modifying drugsfor rpAD due to the involvement of Tau abnormalities<br/>in rpAD neurodegeneration. To determine whether Tau is a suitable therapeutic target, in silico<br/>tools were used to analyse the interaction of proteins isolated by Tau IP. It is identified that<br/>proteins interact with MAPT during the pathology of disease and play a role in progression of<br/>rpAD. The specific interaction between the MAPT region belonging from the MTB domain<br/>2MZ7 and its interactors Neuromodulin, Synaptophysin and RhoA were investigated using<br/>molecular docking and visualization tools like PyRx, PyMOL, Discovery Studio, and LigPlot+<br/>and binding energies and bonding between the amino acids was observed and evaluated.<br/>Protein network analysis revealed an aberration towards apoptotic pathway and signaling<br/>pathway. Furthermore, binding of different drug compounds including Methamphetamine,<br/>Ascorbic acid and Doxorubicin were evaluated through docking in silico. Doxorubicin showed<br/>the highest binding energy of -6.0 kcal/mol with 2MZ7. These drug compounds and their<br/>interaction with 2MZ7 yielding high binding affinity shows that binding site of MAPT can be<br/>blocked using Doxorubicin to prevent the interaction of pathological proteins that are involved<br/>in the accelerated progression of rpAD. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | MS Biomedical Sciences (BMS) |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Supervisor : Dr. Aneeqa Noor |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://10.250.8.41:8080/xmlui/handle/123456789/32267">http://10.250.8.41:8080/xmlui/handle/123456789/32267</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Koha item type | Thesis |
| Withdrawn status | Permanent Location | Current Location | Shelving location | Date acquired | Full call number | Barcode | Koha item type |
|---|---|---|---|---|---|---|---|
| School of Mechanical & Manufacturing Engineering (SMME) | School of Mechanical & Manufacturing Engineering (SMME) | E-Books | 02/13/2024 | 610 | SMME-TH-818 | Thesis |